New Asthma Inhaler Shows Big Promise in Late-Stage TrialsAstraZeneca's Breztri Aerosphere shows significant improvements in asthma treatment, outperforming dual therapies in clinical trials.
AstraZeneca Bets Big on Cell Therapy with $1B ISOBiotech AcquisitionAstraZeneca will acquire ISOBiotech for $1 billion, enhancing its cell therapy capabilities and reducing treatment times significantly.
AstraZeneca Bets on New Cancer Treatments By Acquiring Fusion Pharmaceuticals for $2 Billion [AlphaEconomy=(Chicago) Jisun Kim Correspondent] AstraZeneca is acquiring Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company. AstraZeneca said on Nov. 18 (local time) that it is acquiring Fusion Pharmaceuticals for about $20 billion in cash as it bets on next-generation cancer treatments...
Must-Reads
1
Coupang discloses 33m-user data breach to US regulators
LATEST
2
N. Korea's Kim pays respects to late father at family mausoleum on death anniversary
LATEST
3
Ex-vice land minister arrested over favoritism allegations related to presidential residence relocation
LATEST
4
Seoul stocks open higher amid mixed US job data
LATEST
5
US job growth snaps back; shutdown distorts unemployment rate
New Asthma Inhaler Shows Big Promise in Late-Stage Trials AstraZeneca's Breztri Aerosphere shows significant improvements in asthma treatment, outperforming dual therapies in clinical trials.
AstraZeneca Bets Big on Cell Therapy with $1B ISOBiotech Acquisition AstraZeneca will acquire ISOBiotech for $1 billion, enhancing its cell therapy capabilities and reducing treatment times significantly.
AstraZeneca Bets on New Cancer Treatments By Acquiring Fusion Pharmaceuticals for $2 Billion [AlphaEconomy=(Chicago) Jisun Kim Correspondent] AstraZeneca is acquiring Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company. AstraZeneca said on Nov. 18 (local time) that it is acquiring Fusion Pharmaceuticals for about $20 billion in cash as it bets on next-generation cancer treatments...
Hot Topics